Beta Bionics, Inc.
Securities Class Action Lawsuit
Class Period: July 30, 2025 – February 24, 2026
What Is the Beta Bionics, Inc. (BBNX) Class Action Lawsuit About?
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Beta Bionics securities between July 30, 2025, and February 24, 2026, both dates inclusive (the "Class Period").
Such investors are encouraged to join this case by completing the form on this page or calling 917-590-0911.
What Does the Beta Bionics, Inc. Securities Class Action Allege?
The Complaint alleges that throughout the Class Period, Defendants made false and misleading statements and/or failed to disclose that:
- 1the FDA’s observations concerning the iLet Bionic Pancreas insulin pump extended beyond the Company’s criteria for determining which customer complaints were reportable;
- 2the FDA had identified deficiencies involving the Company’s quality management system, its investigation and correction of known device malfunctions, and its risk analysis for the iLet;
- 3the customer complaints the Company failed to report included serious injuries, rather than only minor events requiring no medical intervention;
- 4accordingly, Defendants materially understated the nature and severity of the FDA’s findings and the safety and regulatory risks affecting the iLet; and
- 5as a result, Defendants’ positive statements concerning the safety, efficacy, and commercial prospects of the iLet, as well as the Company’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis.
Key Dates
Dates are taken from the filed complaint and do not determine eligibility.
How Is Beta Bionics (NASDAQ: BBNX) Stock Trading Today?
What Happens After You Contact Us?
Submit your information
Takes about a minute. Share count and statements are optional.
We review your transactions
Our team analyzes your trades against the class period at no cost.
We keep you updated
We'll contact you about your options and next steps.
Submitting information does not create an attorney-client relationship. You do not need to serve as lead plaintiff to share in any recovery.
How Is BG&G Representing Investors in Securities Class Actions?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
Frequently Asked Questions
Who is eligible to join the Beta Bionics class action?
Investors who purchased or otherwise acquired Beta Bionics securities during the Class Period, July 30, 2025 – February 24, 2026, and suffered an overall net loss may be eligible to participate in a recovery. Eligibility depends on the class definition and your transaction history.
Do I need to be lead plaintiff to recover?
No. You do not need to serve as Lead Plaintiff to participate as a class member or share in a recovery. The Lead Plaintiff directs the litigation on behalf of the class, while other eligible class members are represented and may submit a claim if a settlement is reached.
I sold my shares — can I still participate?
Yes. Eligibility is generally based on when you purchased the shares and whether your overall investment resulted in a net loss, not on whether you still hold them. You may still be eligible even if you sold before the lawsuit was filed or before a settlement.
Does it cost anything to participate?
No. Securities class actions are handled on a contingency-fee basis. The law firms advance the litigation costs and are paid only if the case succeeds, subject to court approval. Class members do not pay legal fees directly.
What documents should I have ready?
Gather brokerage statements or trade confirmations showing your purchases, sales, transfers, and current holdings in the relevant security. Helpful details include transaction dates, share counts, prices, and the accounts in which the trades occurred.
What happens if I miss the November 3, 2026 deadline?
The November 3, 2026 deadline applies to seeking appointment as Lead Plaintiff. Missing it generally does not prevent an otherwise eligible investor from remaining a class member, filing a claim, or receiving a settlement share. Any later settlement claim deadline is separate and must still be followed.